GT 1708F
Alternative Names: GT 1708; GT1708FLatest Information Update: 08 Jan 2025
At a glance
- Originator Suzhou Kintor Pharmaceuticals
- Class Antineoplastics; Pyrimidines
- Mechanism of Action Hedgehog cell signalling pathway inhibitors; SMO protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Leukaemia
- Preclinical Acute myeloid leukaemia; Idiopathic pulmonary fibrosis
- No development reported Basal cell cancer
Most Recent Events
- 31 Dec 2024 GT 1708F is still in phase I trials in Leukaemia in China (Kintor Pharmaceutical pipeline, December 2024)
- 28 May 2024 No recent reports of development identified for phase-I development in Basal-cell-cancer in USA
- 28 May 2024 No recent reports of development identified for phase-I development in Leukaemia in China